China Securities Network News (Wang Luo) Zhongzhu Medical announced on the evening of November 8 that it intends to hold the company's third extraordinary shareholders' meeting in 2021 on November 17 to consider the plan for restructuring the company's debtor Shenzhen Yiyi Group.
According to the announcement, on 26 October 2021, Zhongzhu Medical received the "Letter of Consultation on Whether to Support shareholders' application for reorganization of the debtor" from Beijing Zhong Lun (Shenzhen) Law Firm, the bankruptcy administrator of Shenzhen Yiyi Investment Holding Group Co., Ltd. In order to promote the bankruptcy procedure of the One Group, Liu Danning, the controlling shareholder of the One Group, submitted an application to the Shenzhen Intermediate People's Court to carry out bankruptcy reorganization of the One Group. The Shenzhen Intermediate People's Court requested Liu Danning to submit to the court within a time limit written documents clearly expressing its support for the reorganization of the Yiyi Group, and the bankruptcy administrator Zhong Lun Law Firm now requires the creditors to give a written reply on whether to support shareholder Liu Danning's application for reorganization of the debtor.
Previously, the total amount of debt recognition of Zhongzhu Medical and its subsidiaries to the Yiyi Group was 313 million yuan, which was caused by performance betting and its subsequent cashing problems.
Zhongzhu Medical, formerly known as Qianjiang Pharmaceutical, is mainly engaged in the production and sales of eye drops, injections, APIs and other products, and was listed in May 2001. In February 2016, Zhongzhu Holdings purchased 100% of the equity of Integrated Medical held by Shenzhen Yiyi Investment Holding Group Co., Ltd., Yizheng run Asset Management Co., Ltd., Jin Yixin and Investment and Development Co., Ltd. for 1.9 billion yuan, extending the company's business to the field of medical devices such as tumor radiotherapy, and renaming it "Zhongzhu Medical".
On April 27, 2018, Zhongzhu Medical issued an announcement that the total deducted non-net profit of One Healthcare from 2015 to 2017 was 395 million yuan, lower than the promised 415 million yuan, and the profit difference was 19.7481 million yuan, which means that one group, one zhengrun, Jinyixin and should be compensated for performance.
In February 2019, Zhongzhu Medical took the One Group, One Zhengrun, Jin Yixinhe to court, demanding that the above-mentioned shareholders pay compensation, return dividend income, and compensate for the occupation of funds and lawyers' fees totaling 262 million yuan.